Parsippany, New Jersey-based Zoetis Inc. (ZTS) discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry. Valued at $33.5 billion by market cap, the company also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. The world’s leading animal health company is expected to announce its fiscal third-quarter earnings for 2026 before the market opens on Thursday, Nov. 5.
Ahead of the event, analysts expect Zoetis to report a profit of $1.51 per share on a diluted basis, down 11.2% from $1.70 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.